nonprofit logo

Quantum Leap Healthcare Collaborative

Learn about this cause: What are the reviews? Is it Legit? Do I like the mission? What is the CEO's salary?

EIN: 204284925 ✦ San francisco, CA ✦ Designated as a 501(c)(3)

Shop smarter and support your favorite cause at the same time! With the Give Freely browser extension, you'll automatically save money with coupons, and partner stores will donate to your chosen charity - at no extra cost to you. Start giving back with a single click. It's safe, free, and spam-free, guaranteed!

Overview

What is Quantum Leap Healthcare Collaborative?

Quantum Leap Healthcare Collaborative is a nonprofit organization based in San Francisco, California, with a mission to support healthcare research organizations, specifically those focused on breast cancer. They provide management and financial assistance to further their initiatives. One of their notable projects is the I-SPY Trials. This program aims to revolutionize clinical trials by identifying the right drug for the right patient at the optimal time, reducing costs, and shortening the overall trial duration. The I-SPY Trials integrate various phases to create a pipeline of novel breast cancer agents and accelerate the process of bringing these drugs to market. The organization has a workforce of 113 employees.


Official website here: www.quantumleaphealth.org

What are the reviews and ratings of this charity?

Charity Navigator Rating: 99% (Four-Star out of Four Star rating) from Charity Navigator.

Quantum Leap Healthcare Collaborative has demonstrated exceptional performance in accountability and finance, achieving a nearly perfect score of 99%. This high rating reflects the organization’s commitment to transparency and responsible financial management, with 92% of its board members being independent, which enhances governance and ethical oversight.

The organization excels in various categories, including having a comprehensive audit and oversight committee, conflict of interest policies, and whistleblower protections, all of which are crucial for maintaining integrity. Additionally, the program expense ratio is notably high at 94.44%, indicating that a significant portion of funds is allocated directly to programs, maximizing the impact of donations.

While the organization has a strong financial foundation and governance structure, the liabilities to assets ratio of 50.67% suggests a moderate level of financial leverage. However, this is still within a healthy range and demonstrates that Quantum Leap Healthcare Collaborative effectively manages its resources to fulfill its mission. Overall, the organization is well-regarded for its financial stewardship and commitment to its goals.


This AI summary has been generated from information found on Charity Navigator.

Is Quantum Leap Healthcare Collaborative legitimate?

Quantum Leap Healthcare Collaborative is a legitimate nonprofit organization registered as a 501(c)(3) entity. Quantum Leap Healthcare Collaborative submitted a form 990, which is a tax form used by tax-exempt organizations in the U.S., indicating its operational transparency and adherence to regulatory requirements. Donations to this organization are tax deductible.


Heare are some key statistics you may want to consider:

Executive Compensation: $1,090,719
Professional Fundraising Fees: $0
Other Salaries and Wages: $12,102,560

For more financial information, click here


Official website here: www.quantumleaphealth.org

What is the mission statement of Quantum Leap Healthcare Collaborative?

The Quantum Leap Healthcare Collaborative is dedicated to supporting healthcare research organizations, with a focus on breast cancer research and treatment. They sponsor innovative clinical trials, such as the I-SPY Trials, which aim to match the right drug to the right patient at the most beneficial time, reducing overall costs, time, and patients required to bring new drugs to market. The I-SPY Trials program integrates phase I, II, and future phases, building a pipeline of novel agents and accelerating the identification of high-risk breast cancer patients who will benefit from these new agents. Ultimately, the Collaborative's mission is to advance healthcare research and treatments, particularly for breast cancer, to improve patient outcomes.


Official website here: www.quantumleaphealth.org

Who is the CEO of Quantum Leap Healthcare Collaborative?

James Palazzolo is the Chairman of Quantum Leap Healthcare Collaborative. The CEO's salary of Quantum Leap Healthcare Collaborative is $508,333 and their total compensation is $548,746.


Official website here: www.quantumleaphealth.org

What is the revenue of Quantum Leap Healthcare Collaborative?

Quantum Leap Healthcare Collaborative's revenue in 2022 was $47,253,845.


Official website here: www.quantumleaphealth.org

Who are the executives of Quantum Leap Healthcare Collaborative and what are their salaries?

The average compensation at Quantum Leap Healthcare Collaborative during 2022 was $116,755. There are 113 employees and 12 volunteers at Quantum Leap Healthcare Collaborative.


Here are 21 key members and their salaries (Quantum Leap Healthcare Collaborative's CEO's salary is $508,333 and their total compensation is $548,746):


Dave Mandelkern (Chairman)
  • Compensation: $120,000
  • Related: $0
  • Other: $0
Laura Esserman (Director, Cofounder)
  • Compensation: $0
  • Related: $0
  • Other: $0
Jeffrey Pfeffer (Director, Cofounder)
  • Compensation: $0
  • Related: $0
  • Other: $0
Susan Foley (Treasurer)
  • Compensation: $0
  • Related: $0
  • Other: $0
Anna Barker (Director)
  • Compensation: $0
  • Related: $0
  • Other: $0
Lucas De Breed (Director)
  • Compensation: $0
  • Related: $0
  • Other: $0
Michele Markus (Director)
  • Compensation: $0
  • Related: $0
  • Other: $0
Robert Patterson (Director)
  • Compensation: $0
  • Related: $0
  • Other: $0
Robyn Lawrie Rutledge (Director)
  • Compensation: $0
  • Related: $0
  • Other: $0
Gregory C Simon (Director)
  • Compensation: $0
  • Related: $0
  • Other: $0
Mark Simon (Director)
  • Compensation: $0
  • Related: $0
  • Other: $0
N Marcus Thygeson (Director)
  • Compensation: $0
  • Related: $0
  • Other: $0
Lambert Van Der Walde (Director)
  • Compensation: $0
  • Related: $0
  • Other: $0
Kathryn Watson-Feiner (Vice President Of Finance And Administration)
  • Compensation: $305,989
  • Related: $0
  • Other: $12,429
James Palazzolo (Ceo)
  • Compensation: $508,333
  • Related: $0
  • Other: $40,413
Adam Asare (Chief Data Officer)
  • Compensation: $212,462
  • Related: $0
  • Other: $11,095
Karyn Digiorgio (Chief Collaboration Officer)
  • Compensation: $278,506
  • Related: $0
  • Other: $33,256
Tracey Heather (Director Of Development)
  • Compensation: $231,040
  • Related: $0
  • Other: $44,304
Paul Henderson (Sr. Director Of Collaborations)
  • Compensation: $231,615
  • Related: $0
  • Other: $44,883
Maria Pitsiouni (Director, Clinical Operations Oncology)
  • Compensation: $216,516
  • Related: $0
  • Other: $34,843
Sara Horton (Executive Director, Access & Diversity)
  • Compensation: $235,513
  • Related: $0
  • Other: $4,250


Official website here: www.quantumleaphealth.org

Where can I find the form 990 for Quantum Leap Healthcare Collaborative?

Quantum Leap Healthcare Collaborative's most recent form 990 was submitted in 2022 and can be accessed here.


Official website here: www.quantumleaphealth.org

Learn more at the official website: www.quantumleaphealth.org

Mission Statement of Quantum Leap Healthcare Collaborative

Quantum Leap Healthcare Collaborative, a healthcare research organization supporter, is dedicated to providing management and financial assistance, with a significant focus on breast cancer research and treatment. The nonprofit organization plays a vital role in the healthcare sector by sponsoring groundbreaking initiatives like the I-SPY Trials.

The I-SPY Trials, an innovative program by Quantum Leap Healthcare Collaborative, redefines clinical trials with the goal to match the right drug with the right patient at the most beneficial time. This approach aims to reduce overall costs, time, and the number of patients required to bring new drugs to market. The I-SPY Trials consist of three distinct phases, I-SPY 1, I-SPY 2, and future phases, all linked together to create a pipeline of novel agents and expedite the identification of high-risk breast cancer patients who will benefit from these new agents. The program strives to get these drugs into the clinic efficiently.

Shop smarter and support your favorite cause with the Give Freely browser extension. Save money with coupons and donate to charity with a single click. Download now!

Impact




October, 2024

Quantum Leap Healthcare Collaborative significantly impacts the field of breast cancer research and treatment through innovative approaches to clinical trials. By sponsoring the I-SPY Trials, it re-engineers traditional trial methodologies, aiming to match the right drug with the right patient at the optimal time for therapeutic benefit. This efficiency leads to faster identification and development of effective treatments, ultimately reducing both the costs and time involved in bringing new drugs to market.

The integration of multiple trial phases (I-SPY Phase 1, I-SPY 2, and future phases) fosters a robust pipeline of novel agents. This strategic approach not only accelerates the testing process but also focuses on high-risk breast cancer patients who are most likely to benefit from these new therapies. By streamlining this process, Quantum Leap enhances the overall effectiveness of breast cancer treatment research, making tangible progress in combating this disease and improving patient outcomes.




This information is meant to be a general summary of Quantum Leap Healthcare Collaborative. Please take the time to review official sources before making any decisions based upon the content provided here.


Financials

This financial information is from Propublica.

Revenue
$47,253,845 (2022)
Expenses
$47,240,395 (2022)
Efficiency

Other financial information:

This information is from the most recently submitted tax form from this organization, which was in 2022.

  • Investment Income: $450,842
  • Program Service Revenue: $27,865,728
  • Gross Receipts: $130,915,690

Assets and Liabilities:

  • Total Assets: $60,913,948
  • Total Liabilities: $30,870,765
  • Net Assets: $30,043,183

Want to help this charity, for free? You can click here to learn more about Give Freely

Programs

Programs are reported by nonprofits in their tax forms and are normally their tax-exempt activities.

CLINICAL TRIAL CONTRAC

Revenue

$26,914,608

CONSULTING AND RESEARC

Revenue

$951,120

Organization Details

Founding Year

2005

Principal Officer

James Palazzolo

Main Address

499 ILLINOIS AVE 200, SAN FRANCISCO, CA, 94158

NTEE Category

Code: P20 - Human services

If you are a representative of Quantum Leap Healthcare Collaborative and wish to learn more about how Give Freely can help you raise funds, please click here: https://givefreely.com/nonprofits/. Our services are offered at no cost to your organization.